Abstract
Understanding the trajectory of the daily numbers of deaths in people with CoVID-19 is essential to decisions on the response to the CoVID-19 pandemic. Estimating this trajectory from data on numbers of deaths is complicated by the delay between deaths occurring and their being reported to the authorities. In England, Public Health England receives death reports from a number of sources and the reporting delay is typically several days, but can be several weeks. Delayed reporting results in considerable uncertainty about the number of deaths that occurred on the most recent days. In this article, we estimate the number of deaths per day in each of five age strata within seven English regions. We use a Bayesian hierarchical model that involves a submodel for the number of deaths per day and a submodel for the reporting delay distribution. This model accounts for reporting-day effects and longer-term changes over time in the delay distribution. We show how the model can be fitted in a computationally efficient way when the delay distribution is same in multiple strata, e.g. over a wide range of ages.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Medical Research Council (Unit programme numbers MC UU 00002/10 and MC UU 00002/11) in partnership with Public Health England. We acknowledge the support of the PHE Epidemiology Cell in consistently providing the data streams used.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This manuscript was approved by senior colleagues at Public Health England, including Professor Yvonne Doyle, the Medical Director.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos